Picking Up the Pieces: How Biogen Is Dealing With Discontinued Alzheimer’s Trial
Biogen shares made a slight gain early on Monday after the firm made an SEC filing indicating that it will be buying back a sizable amount of stock.
Biogen shares made a slight gain early on Monday after the firm made an SEC filing indicating that it will be buying back a sizable amount of stock.
Neurotrope Inc. (NASDAQ: NTRP) may be a winner by default in the battle against Alzheimer’s disease after shares of Biogen Inc. (NASDAQ: BIIB | BIIB Price Prediction) suffered handily with the announcement that it…
Biogen shares were crushed in Thursday’s session after the firm announced that it would be discontinuing its late-stage trial for Alzheimer’s disease.
Gene therapy may become the next frontier for drug companies seeking to make billions of dollars improving or even curing certain diseases.
Pfizer is looking to collaborate with Vivet on the development of its proprietary treatment for Wilson disease.
AbbVie and patients suffering from multiple myeloma have seen some additional bad news from the FDA.
Altimmune shares surged on Tuesday following results from its midstage study of a intranasal influenza vaccine candidate.
Dermira shares more than doubled on Monday after the firm announced midstage results from its Eczema study.
PhaseBio shares more than doubled on Monday after the firm released results from an early-stage clinical trial of its antiplatelet reversal agent.
We screened our 24/7 Wall St. research database and found five biotech stocks trading under the $10 level that could provide investors with some solid upside potential.
Karyopharm shares jumped on Friday after the firm announced an FDA update from the FDA on its treatment for myeloma.
Johnson & Johnson shares dipped on Thursday on news that a California jury awarded $29 million to a woman that claimed its talcum-powder-based products caused her cancer.
Patients suffering anemia due to chronic kidney disease are sure to be content with new positive top-line results from two Phase 3 active-controlled pivotal studies.
The February 28 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.